S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:RANI

Rani Therapeutics (RANI) Stock Price, News & Analysis

$3.11
+0.08 (+2.64%)
(As of 03/28/2024 ET)
Today's Range
$3.03
$3.25
50-Day Range
$3.03
$3.80
52-Week Range
$1.82
$5.81
Volume
128,133 shs
Average Volume
80,523 shs
Market Capitalization
$155.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.00

Rani Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
350.2% Upside
$14.00 Price Target
Short Interest
Bearish
16.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.62mentions of Rani Therapeutics in the last 14 days
Based on 14 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.98) to ($0.81) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.34 out of 5 stars

Medical Sector

757th out of 938 stocks

Pharmaceutical Preparations Industry

341st out of 423 stocks

RANI stock logo

About Rani Therapeutics Stock (NASDAQ:RANI)

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including large molecules, such as peptides, proteins, and antibodies. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company was incorporated in 2012 and is headquartered in San Jose, California.

RANI Stock Price History

RANI Stock News Headlines

A lot of people are making this costly mistake
You may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time.
RANI: 2023 Results
Q4 2023 Rani Therapeutics Holdings Inc Earnings Call
A lot of people are making this costly mistake
You may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time.
Recap: Rani Therapeutics Hldgs Q4 Earnings
Earnings Outlook For Rani Therapeutics Hldgs
Rani Therapeutics (RANI) to Release Earnings on Wednesday
RANI Apr 2024 2.500 put
RANI Apr 2024 5.000 put
See More Headlines
Receive RANI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rani Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/22/2023
Today
3/28/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RANI
Fax
N/A
Employees
140
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.00
High Stock Price Target
$24.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+350.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-33,970,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$2.72 million
Book Value
$0.51 per share

Miscellaneous

Free Float
24,989,000
Market Cap
$155.50 million
Optionable
Optionable
Beta
0.97
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Mir A. Imran (Age 68)
    Executive Chairman
    Comp: $80k
  • Mr. Talat Imran (Age 42)
    CEO & Director
    Comp: $827k
  • Mr. Svai S. Sanford (Age 54)
    Chief Financial Officer
    Comp: $661.6k
  • Dr. Mir Hashim (Age 64)
    Chief Scientific Officer
    Comp: $661.6k
  • Mr. Eric Groen (Age 53)
    General Counsel
  • Ms. Bella Vazquez
    Vice President of Human Resources
  • Ms. Kate McKinley M.B.A.
    Chief Business Officer
  • Ms. Arvinder Dhalla
    Vice President of Clinical Development

RANI Stock Analysis - Frequently Asked Questions

Should I buy or sell Rani Therapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rani Therapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RANI shares.
View RANI analyst ratings
or view top-rated stocks.

What is Rani Therapeutics' stock price target for 2024?

6 Wall Street analysts have issued 1 year price objectives for Rani Therapeutics' shares. Their RANI share price targets range from $8.00 to $24.00. On average, they expect the company's stock price to reach $14.00 in the next year. This suggests a possible upside of 350.2% from the stock's current price.
View analysts price targets for RANI
or view top-rated stocks among Wall Street analysts.

How have RANI shares performed in 2024?

Rani Therapeutics' stock was trading at $3.32 on January 1st, 2024. Since then, RANI stock has decreased by 6.3% and is now trading at $3.11.
View the best growth stocks for 2024 here
.

When is Rani Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our RANI earnings forecast
.

How were Rani Therapeutics' earnings last quarter?

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) posted its earnings results on Wednesday, March, 22nd. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.34) by $0.01. During the same period in the prior year, the firm posted ($0.27) EPS.

When did Rani Therapeutics IPO?

Rani Therapeutics (RANI) raised $100 million in an IPO on Friday, July 30th 2021. The company issued 6,666,667 shares at $14.00-$16.00 per share.

Who are Rani Therapeutics' major shareholders?

Rani Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Alpha Square Group S LLC (0.12%), Stifel Financial Corp (0.10%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Cortes Isidoro Alfonso Quiroga, Maulik Nanavaty, Mir A Imran, South Cone Investments Limited and Talat Imran.
View institutional ownership trends
.

How do I buy shares of Rani Therapeutics?

Shares of RANI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RANI) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners